Locations
Île-de-France, France · Paris, France · Paris, France
industry
Biotechnology · DeepTech · Health
Size
11-50 employees
Stage
Series B
founded in
2014
Eligo Bioscience is a pioneer in genetic engineering, focusing on in vivo gene editing of the microbiome through its proprietary GEM platform. This first-in-class technology aims to edit the microbiome gene repertoire to address various diseases linked to bacterial genes. Founded by leading scientists in synthetic biology and microbiology, Eligo differentiates itself with its innovative approach to developing next-generation antimicrobials, leveraging CRISPR technology and engineered phage capsids. The company is positioned to make significant impacts in the healthcare sector, particularly in combating antibiotic resistance and improving patient outcomes.
Something looks off?On-site & Remote